AARD Aardvark Therapeutics, Inc.
Nasdaq · SEC CIK 1774857 · EDGAR
- Bought, last 12 months
- $144.6K 2 purchases by 2 insiders
- Sold, last 12 months
- $395.0K 1 sales by 1 insiders
- Filings on record
- 30 since 2025-02-19, latest 2026-09-11 20:14
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Sun Nelson | See Remarks | $43.2K | $395.0K |
| Lee Tien-Li | CEO, Dir, 10% | $101.4K | — |
| Jones Bryan | COO | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-11 20:14 | 2026-09-10+ | AARD | Sun Nelson | See Remarks | S - Sale | $5.15 | -76.8K | 35.5K | -68% | -$395.0K |
| 2025-12-12 | 2025-12-11 | AARD | Lee Tien-Li | CEO, Dir, 10% | P - Purchase | $14.49 | +7,000 | 1.55M | +0.5% | +$101.4K | |
| 2025-12-12 | 2025-12-11 | AARD | Sun Nelson | CFO | P - Purchase | $14.40 | +3,000 | 108.5K | +3% | +$43.2K | |
| D | 2025-10-16 | 2025-10-15 | AARD | Jones Bryan | COO | M - OptEx | $4.24 | +1,250 | 1,250 | New | +$5,300 |
| D | 2025-10-16 | 2025-10-15 | AARD | Lee Tien-Li | CEO, Dir, 10% | M - OptEx | $4.24 | +1,229 | 1.54M | +0.1% | +$5,211 |
| M | 2025-09-16 | 2025-09-15 | AARD | Lee Tien-Li | CEO, Dir, 10% | P - Purchase | $9.66 | +10.0K | 1.54M | +0.7% | +$96.6K |
| M | 2025-09-12 | 2025-09-10+ | AARD | Lee Tien-Li | CEO, Dir, 10% | P - Purchase | $8.03 | +20.0K | 1.53M | +1% | +$160.6K |
| 2025-09-10 | 2025-09-09 | AARD | Sun Nelson | CFO | P - Purchase | $8.07 | +6,000 | 105.5K | +6% | +$48.4K | |
| D | 2025-08-29 | 2025-08-28 | AARD | Lee Tien-Li | CEO, Dir, 10% | M - OptEx | $4.24 | +17.2K | 1.51M | +1% | +$73.0K |
| D | 2025-02-19 | 2025-02-14 | AARD | Sun Nelson | CFO | P - Purchase | $16.00 | +10.0K | 99.5K | +11% | +$160.0K |
| D | 2025-02-19 | 2025-02-14 | AARD | Sun Nelson | CFO | C - Cnv Deriv | — | +7,001 | 89.5K | +8% | — |
| DMI | 2025-02-19 | 2025-02-14 | AARD | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% | C - Cnv Deriv | — | +2.67M | 333.4K | New | — |
| DMI | 2025-02-19 | 2025-02-14 | AARD | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% | P - Purchase | $16.00 | +1.25M | 2.96M | +73% | +$20.00M |
| DI | 2025-02-19 | 2025-02-14 | AARD | Chi Jeffrey | Dir | C - Cnv Deriv | — | +133.4K | 133.4K | New | — |
| DMI | 2025-02-19 | 2025-02-14 | AARD | Vickers Venture Fund VI Pte Ltd | 10% | C - Cnv Deriv | — | +2.05M | 2.05M | New | — |
| D | 2025-02-19 | 2025-02-14 | AARD | Lee Tien-Li | CEO, Dir, 10% | P - Purchase | $16.00 | +16.5K | 1.50M | +1% | +$264.7K |
| D | 2025-02-19 | 2025-02-14 | AARD | Lee Tien-Li | CEO, Dir, 10% | C - Cnv Deriv | — | +41.3K | 1.48M | +3% | — |
| DI | 2025-02-19 | 2025-02-14 | AARD | Chen Bihua | Former 10% Owner | P - Purchase | $16.00 | +187.5K | 987.7K | +23% | +$3.00M |
| DI | 2025-02-19 | 2025-02-14 | AARD | Chen Bihua | Former 10% Owner | C - Cnv Deriv | — | +800.2K | 800.2K | New | — |
Purchase Sale Sale after option exercise All abbreviations